Bemærk: Kan ikke leveres før jul.
Forventes på lager: 28-06-2018
A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies.
| Forlag | Springer International Publishing AG |
| Forfattere | Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli |
| Type | Bog |
| Format | Paperback / softback |
| Sprog | Engelsk |
| Udgave | Softcover reprint of the original 1st ed. 2017 |
| Udgivelsesdato | 28-06-2018 |
| Første udgivelsesår | 2018 |
| Illustrationer | 11 Illustrations, color; VI, 99 p. 11 illus. in color. |
| Originalsprog | Switzerland |
| Sideantal | 99 |
| Indbinding | Paperback / softback |
| Forlag | Springer International Publishing AG |
| Sideoplysninger | 99 pages, 11 Illustrations, color; VI, 99 p. 11 illus. in color. |
| Mål | 235 x 155 |
| ISBN-13 / EAN-13 | 9783319834177 |